Investor Relations

AVEO Oncology is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates.

NASDAQ | AVEO (Common Stock)
$1.19 + 0.01
Stock chart for: AVEO.O.  Currently trading at $1.19 with a 52 week high of $3.50 and a 52 week low of $0.61.
11/30/15 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Oncology Reports Third Quarter 2015 Financial Results and Provides Business UpdateRead More
AVEO Announces Chairman Tuan Ha-Ngoc Steps DownRead More
AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related AntibodiesRead More

Latest Event